Seattle Children’s Brings First-of-its-kind Precision Medicine Clinical Trial to Inflammatory Bowel Disease, Bone Marrow Transplant Patients

SEATTLE – May 23, 2017 – In an effort to find new strategies to personalize treatment for pediatric patients, Seattle Children’s has opened the first clinical trial applying next-generation T-cell receptor (TCR) sequencing and single-cell gene expression analysis to better understand how the immune system drives both inflammatory bowel disease (IBD) in pediatric autoimmunity patients and graft-versus host disease (GVHD) in pediatric bone marrow transplant (BMT) patients.